상세 보기
AM251 suppresses the viability of HepG2 cells through the AMPK (AMP-activated protein kinase)-JNK (c-Jun N-terminal kinase)-ATF3 (activating transcription factor 3) pathway
- Lee, Yun Mi;
- Uhm, Kyung-Ok;
- Lee, Eun Soo;
- Kwon, Joseph;
- Park, Sun Hwa;
- ... Kim, Hyeon Soo
WEB OF SCIENCE
25SCOPUS
27초록
AM251, a cannabinoid antagonist, has various biological activities. In this study, we found that AM251 suppressed the viability of hepatoma HepG2 cells and also increased phosphorylation of JNK (c-jun N-terminal kinase) and ATF3 (activating transcription factor 3). In addition, AM251 phosphorylated AMPK (AMP-activated protein kinase) in a time and dose-dependent manner. Inhibition of AMPK blocked AM251-induced JNK/ATF3 phosphorylation. Expression of AMPK or treatment with AICAR (5-aminoimidazole-4-carboxy-amide-1-D-ribofuranoside), an AMPK activator, activated the JNK/ATF3 pathways. Together, these results suggest that AM251 may have anti-tumor effects in hepatoma through activation of the AMPK-JNK-ATF3 signal pathway. (c) 2008 Published by Elsevier Inc.
키워드
- 제목
- AM251 suppresses the viability of HepG2 cells through the AMPK (AMP-activated protein kinase)-JNK (c-Jun N-terminal kinase)-ATF3 (activating transcription factor 3) pathway
- 저자
- Lee, Yun Mi; Uhm, Kyung-Ok; Lee, Eun Soo; Kwon, Joseph; Park, Sun Hwa; Kim, Hyeon Soo
- 발행일
- 2008-06-13
- 유형
- Article
- 권
- 370
- 호
- 4
- 페이지
- 641 ~ 645